¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¼¼Á¾´ëÇб³ Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦34Â÷ KSTH Ãß°èÇмú´ëȸ : 2018-09-14

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
¼¼Á¾´ëÇб³ Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦34Â÷ KSTH Ãß°èÇмú´ëȸ : 2018-09-14
±³À°ÀÏÀÚ : 2018-09-14
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ¼¼Á¾ÄÁº¥¼ÇȦ ÁöÇÏ1Ãþ ÄÁÆÛ·±½º·ë ¿Ü 2°³·ë  
±³À°ÁÖÁ¦ : Á¦34Â÷ KSTH Ãß°èÇмú´ëȸ      
ÁÖÃÖ±â°ü : Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ
´ã´çÀÚ : ±èÁø¾Æ
¿¬¶ôó : 042-484-2426  
À̸ÞÀÏ : ksth@thrombo.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, Á¤½Å°ú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, À̺ñÀÎÈÄ°ú, ¿µ»óÀÇÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаúÀÇ»çÇÐ, ¿¹¹æÀÇÇÐ, »ý¸®ÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ÀÇ·á»çȸÇÐ, ÀÇ·áÀ±¸®ÇÐ, ÀÇ·á»çȸ½É¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇÇб³À°, ÀÇ·áÁ¤Ã¥, ÀÇ·á°æ¿µ, ±âŸ
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 40,000¿ø      
ºñ°í »çÀüµî·Ïºñ 3¸¸¿ø, Àü°øÀÇ ¹× ±âŸ 1¸¸¿ø      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 09:30~10:00 Secondary prevention of recurrent VTE after initial treatment in patients with first unprovoked VTE ¢º assessment for thrombosis and bleeding, prediction model of recurrent VTE, DOACs for secondary prevention  È²Çå±Ô(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 10:00~10:30 Selection guide of DOACs and their doses in various clinical situation in patients with VTE  ³ª»óÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 10:30~10:50 Thrombophilia testing in anticoagulated patients  ±èº¸Çö(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 10:50~11:10 Lupus anticoagulant; detection guidelines, testing and interpretation  ¹Ú»óÇõ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 11:10~11:30 Heparin induced thrombocytopenia, what should we know  ¼­¿ïÀÇ´ë(±èÇö°æ) 
È޽Ġ09¿ù 14ÀÏ  11:30~11:45 break  () 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 11:45~12:15 Frontline treatment for chronic ITP  ±èÀ¯¸®(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 12:15~12:45 TPO receptor agonist for chronic ITP  ½Åµ¿¿±(¼­¿ïÀÇ´ë) 
½Ä»ç 09¿ù 14ÀÏ  12:45~13:45 Á¡½É½Ä»ç  () 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 13:45~14:45 cancer VTE; Treatment of Venous thromboembolism in Patient with Cancer  Harry Büller(Academic Medical Center of Amsterdam) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë3 14:45~15:15 Oral presentation  ¹æ¼ö¹Ì,Çö½Å¿µ(¼­¿ïÀÇ´ë,¿¬¼¼´ë ¿øÁÖÀÇ°ú´ëÇÐ) 
È޽Ġ09¿ù 14ÀÏ  15:15~15:30 break  () 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 15:30~16:00 Anti-platelet activity of Ginseoside Rps and their molecular mechanisms  °æºÏ´ë ¼öÀÇ´ë(À̸¸ÈÖ) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 16:00~16:30 Platelet Signaling Pathways: Focus on GPCR  ÃæºÏ´ë ¼öÀÇ´ë(±è¼öÁ¾) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 16:30~16:50 Physiology of VWF  ¿¬¼¼ÀÇ´ë(¼ÛÀç¿ì) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 16:50~17:10 Characterization of a novel Factor VIII having vWF domain fusion and PEG conjugation  ¸ñ¾Ï»ý¸í°úÇבּ¸¼Ò(¿ÀÀÎÀç) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 17:10~17:30 Development of subcutaneous FVIII  ¿¬¼¼ÀÇ´ë(ÇÑÁ¤¿ì) 
±âŸ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 17:30~17:40 Çмú»ó ¹ßÇ¥ ¹× ½Ã»ó  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¼¼Á¾´ëÇб³ Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦34Â÷ KSTH Ãß°èÇмú´ëȸ : 2018-09-14""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѳúÁ¹ÁßÇÐȸ 2018 ICSU 2018 & 1st AKJSC Program(9/13~15) : 2018-09-14
´ÙÀ½±Û ¼øõÇâ´ëÇб³ ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ 2018 °í°üÀý °ñÀý ½ÉÆ÷Áö¿ò : 2018-09-14
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
123 °æºÏ ´ëÇÑÁ¾¾ç³»°úÇÐȸ Best of ASCO 2018 in Korea : 2018-08-25 0 523 2018-07-28
122 ´ëÀü ´ëÇÑ°»³â±âÇÐȸ 2018 ÇÏ°è¿öÅ©¼¥ : 2018-08-25 0 384 2018-07-28
121 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ¼ö¸éÀÇÇÐ:´ÙÇÐÁ¦ Áø·áÀÇ ÀüÇü : 2018-08-25 0 797 2018-07-28
120 ´ë±¸ Ä¥°î°æºÏ´ëÇб³º´¿ø 2018³â È£½ºÇǽºÀÇ·á±â°ü Á¾»çÀÚ º¸¼ö±³À°°úÁ¤ : 2018-08-25 0 1,441 2018-07-28
119 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ±³À°ÀÚ ¼¼¹Ì³ª : 2018-08-25 0 666 2018-07-28
118 ¼­¿ï Çѱ¹À¯¹æ¾ÏÇÐȸ 2018 School of Breast Disease(Day 1) : 2018-08-25 0 578 2018-07-28
117 ´ëÀü ´ëÇѳëÀκ´ÇÐȸ ³ëÀÎȯÀÚÀÇ Ä¡·á¿Í º¯È­ÇÏ´Â ÀÇ·á : 2018-08-25 0 1,182 2018-07-28
116 ºÎ»ê 2018³â ´ëÇÑÁßȯÀÚÀÇÇÐȸ ºÎ»ê¿ï»ê°æ³²Áöȸ NIV ¿öÅ©¼¥ : 2018-08-25 0 892 2018-07-28
115 ÀÎõ 2018³â ´ëÇѺҾÈÀÇÇÐȸ Çϰ迬¼ö±³À° : 2018-08-25 0 619 2018-07-28
114 ¼­¿ï Çѱ¹¿©ÀÚÀÇ»çȸ ¿°Áõ¼º Àå Áúȯ Áø´Ü°ú Ä¡·á / ³»½Ã°æ ¹ßÀü ¿ª»ç : 2018-08-25 0 539 2018-07-28
113 ´ë±¸ ´ëÇѵÎÅëÇÐȸ ´ë±¸, °æºÏÁö¿ª º¸¼ö±³À°(¸¸¼ºÆíµÎÅë Áø´Ü ¹× Ä¡·á 6 ´Ü°è) : 2018-08-25 0 757 2018-07-28
112 °æ±â Á¦ 7ȸ ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¿ò : 2018-08-25 0 611 2018-07-28
111 ¼­¿ï Á¦2ȸ ´ëÇѼҾÆÁßȯÀÚÀÇÇÐȸ ¼Ò¾Æ±â°èȯ±â ¿öÅ©¼ó ¿ÀÀü session(8.25) : 2018-08-25 0 998 2018-07-28
110 ¼­¿ï Á¦2ȸ ´ëÇѼҾÆÁßȯÀÚÀÇÇÐȸ ¼Ò¾Æ±â°èȯ±â ¿öÅ©¼ó Interactive workshop(8.25) : 2018-08-25 0 700 2018-07-28
109 ±¤ÁÖ ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ Á¦99Â÷ Àü³²ºÏÁöȸ ¿¬¼ö°­Á : 2018-08-25 0 621 2018-07-28
1401 | 1402 | 1403 | 1404 | 1405 | 1406 | 1407 | 1408 | 1409 | 1410
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷